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ABSTRACT
Elucidating the mechanisms that underlie metastasis is of paramount 
importance to understanding tumor progression and to the development of novel 
therapeutics. Epithelial to Mesenchymal Transition (EMT) plays a vital role in tumor 
cell dissemination and is regulated by a core cassette of transcription factors. Despite 
recent advances, the molecular pathways that regulate the EMT program have not yet 
been fully delineated. We show that Siah ubiquitin ligases regulate Zeb1 protein, a 
key EMT transcription factor. The induction of EMT in breast cancer cells leads to the 
down-regulation of Siah, while the loss of Siah induces a mesenchymal phenotype, 
concurrent with an up-regulation of Zeb1. Overexpression of Siah in vitro mediates 
Zeb1 degradation, which can be blocked with a Siah peptide inhibitor. Thus, this work 
demonstrates that Siah is a novel regulator of EMT. This work is the first to identify 
a mechanism of post-translational regulation of the key Epithelial to Mesenchymal 
Transition transcription factor Zeb1.
INTRODUCTION
Epithelial to Mesenchymal Transition (EMT), a 
program during which epithelial cells undergo major 
molecular, biochemical and morphological changes 
to adopt a mesenchymal phenotype, plays a role in 
facilitating tumor cell dissemination [1]. EMT, a highly 
conserved process across species, is vital during early 
developmental stages and is typically characterized by 
the loss of epithelial-specific proteins such as E-cadherin 
and by increased expression of mesenchymal markers [1]. 
In the cancer setting, by undergoing EMT, tumor cells 
are equipped with a migratory and invasive phenotype, 
thereby enhancing cell dissemination from the primary 
tumor, entry into the circulation, and survival in the 
circulation and in disseminated sites. EMT also reduces 
cell proliferation and inhibits senescence and apoptosis, 
thus conferring resistance to conventional chemotherapies 
[1, 2]. Triggered by a number of growth factors, most 
notably Transforming Growth Factor-beta (TGF-β), EMT 
is regulated by a core cassette of transcription factors 
including Zeb1, as well as Snail (Snail1), Slug (Snail2), 
Twist1/2 and Zeb2 [3].
Recently published work suggests that Zeb1 is 
the most proximal EMT transcription factor in breast 
cancer, acting via the repression of E-cadherin and the 
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microRNA-200 family [4–7]. Aberrant Zeb1 expression 
has been described in a number of other cancers, 
including colorectal cancer, metastatic lung cancer and 
aggressive uterine cancer [8, 9]. As such, pathological 
EMT is currently being investigated as a candidate for 
therapeutic intervention in cancer patients [1, 10, 11]. 
While post-translational regulatory mechanisms involving 
ubiquitination and proteasomal degradation of Snail, Slug, 
Twist and Zeb2 have been described, the regulation of 
Zeb1 protein abundance is currently unknown [12–15].
On the other hand, Siah proteins have been 
previously shown to play a role in tumorigenesis and 
metastasis [16, 17], however, their involvement in EMT 
has not yet been described. As a family of E3 ubiquitin 
ligases, Siah proteins transfer ubiquitin onto substrates, 
thereby targeting them for degradation by the 26S 
proteasome [16]. In humans, the Siah family consists of 
two members, Siah1 and Siah2, whereas in mice there 
are three members, Siah1a, Siah1b and Siah2 [16]. 
Interestingly, Siah has been reported to act as both an 
oncogene and a tumor suppressor [17]. As an upstream 
regulator of the Sprouty2/Ras, hypoxia-inducible factor 
(HIF) pathways and of the HIPK2 tumor suppressor 
protein, Siah is able to modulate tumor progression 
[18–22]. Accordingly, some studies have shown that Siah2 
blockade inhibits tumor development and metastasis 
[19, 23, 24]. Conversely, some reports have indicated 
that Siah, in particular, Siah1, may function in a 
tumor suppressive manner, by inducing apoptosis and 
sharing similar mechanisms as p53 and p21 [25, 26]. 
Additionally, Siah1 has been demonstrated to be involved 
in the degradation of β-catenin, through interaction with 
adenomatous polyposis coli and p53, in several cancer 
cell types [27–32]. While Siah does appear to have 
contradictory roles in cancer, its involvement in several 
critical signalling pathways makes it an interesting target 
to study in the preclinical and clinical settings.
Here, we show that Siah ubiquitin ligases regulate 
Zeb1 protein levels. The induction of EMT in human 
epithelial breast cancer cells leads to the down-regulation 
of Siah protein expression, while the loss of Siah in 
these cells and in murine breast cancer cells results in a 
mesenchymal phenotype. These data identify Siah as 
a novel regulator of EMT by controlling the abundance 
of the key transcription factor Zeb1, while Siah itself is 
subject to regulation by EMT-inducing factors.
RESULTS
EMT induction causes the down-regulation 
of Siah
To investigate Siah protein levels during EMT, a 
phenotypic switch in the human epithelial MCF-7 breast 
cancer cell line was induced by a treatment of TGF-β and 
TNF-α over a 5-day period. The EMT induction by this 
treatment regimen was confirmed by the complete loss of 
E-cadherin at the protein level in treated cells (Figure 1A). 
Additionally, mesenchymal gene expression (BGN, 
BIN1, FBLN1, MMP2 and N-cadherin) was significantly 
increased in treated cells (Figure 1B). Concurrently, EMT 
transcription factor gene expression (Slug, Snail, Twist, 
Zeb1, Zeb2) in treated cells was significantly increased 
(Figure 1C). Interestingly, the protein expression, but 
not gene expression, of both Siah family members 
was decreased following EMT induction (Figure 1D, 
Supplementary Figure 1A).
The reduction of Siah protein levels was also 
observed in the murine mammary epithelial cell line, 
NMuMG, when treated with TGF-β to induce EMT. 
NMuMG cells normally have an epithelial appearance, 
consisting of regular cellular dimensions and the formation 
of discrete epithelial islands. However, these cells 
adopted a mesenchymal phenotype, as characterized by 
elongated cell bodies and by growth as dispersed, single 
cells or in small groups, as early as 48 hours after the 
initiation of TGF-β treatment (Figure 1E). EMT induction 
was verified by the gradual decrease in E-cadherin and 
increase in N-cadherin protein expression, respectively, 
over the course of treatment (Figure 1F). This was also 
associated with increased expression of mesenchymal 
genes (Figure 1G, Supplementary Figure 1B). In addition, 
an increase in gene expression of EMT transcription 
factors was also observed in treated cells (Figure 1H, 
Supplementary Figure 1C). At the protein level, Siah1 
and Siah2 expression was effectively reduced by 24 and 
96 hours, respectively, following treatment initiation 
(Figure 1I). However, no such changes were observed 
at the gene expression level (Supplementary Figure 1D). 
This data shows that Siah protein levels are reduced in 
cells undergoing EMT.
Siah knockdown leads to a mesenchymal 
gene expression profile
To assess if a decrease of Siah has a functional 
role during EMT, Siah gene expression levels were 
reduced by siRNA-mediated knockdown in MCF-7 
cells (Dharmacon SMARTpool; Figure 2A, Individual 
siRNAs; Supplementary Figure 2A). The knockdown of 
Siah1 and/or Siah2 was sufficient to up-regulate EMT 
target genes (Figure 2B, Supplementary Figure 2B) 
and transcription factors (Figure 2C, Supplementary 
Figure 2B), suggesting that the loss of Siah alone is able to 
initiate the induction of EMT. Interestingly, the knockdown 
of Siah1 led to an increase in Siah2 expression, indicative 
of a compensatory mechanism. While demonstrating 
lesser penetrance, similar trends in EMT target and 
transcription factor gene expression was observed 
when Siah gene expression levels were mediated by 
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siRNA-knockdown (Dharmacon SMARTpool) in NMuMG 
cells (Supplementary Figure 2E, F). Next, to determine 
which EMT transcription factor mediated this specific 
induction of EMT, we focused on Zeb1 as it is the most 
proximal EMT transcription factor [6]. Thus, any alterations 
in upstream EMT transcription factors should manifest in 
changes of Zeb1 expression. To evaluate whether the loss 
of Siah modulates EMT through Zeb1, expression of Zeb1 
was reduced by knockdown in combination with Siah1 and 
Siah2 knockdown (Figure 2D, Supplementary Figure 2C). 
The EMT gene signature caused by Siah1 and/or Siah2 
knockdown (Figure 2E, Supplementary Figure 2D) was 
partially reverted by the reduction of Zeb1 in MCF-7 cells 
(Figure 2F, Supplementary Figure 2D). While in NMuMG 
cells, this pattern was only observed in N-cadherin gene 
expression, however, this is most likely caused by poor 
Zeb1 knockdown when combined with Siah1a, Siah1b and 
Siah2 siRNAs (Supplementary Figure 2G, H). Overall, this 
suggests that Siah controls EMT through a Zeb1-dependent 
process.
Figure 1: Siah protein levels decrease during EMT. (A) Protein expression levels, as assessed by Western blot, of E-cadherin in 
MCF-7 untreated control cells and cells undergoing EMT, as induced by a combination of TGF-β and TNF-α treatment. Equal loading 
was confirmed by α-tubulin. (B) mRNA expression of mesenchymal genes in untreated control cells and treated MCF-7 cells. qPCR was 
performed in triplicate per biological repeat (n = 4). Data shown as mean ± SEM. (C) mRNA expression, as determined by qPCR performed 
in triplicate per biological repeat (n = 4), of EMT transcription factors in untreated and treated MCF-7 cells. Data shown as mean ± SEM. 
(D) Protein expression of Siah1 and Siah2 in untreated and treated MCF-7 cells, as evaluated by Western blot. Equal loading was confirmed 
by α-tubulin. Relative pixel density of Zeb1 was normalized to respective loading control. (E) Phase contrast photos of NMuMG cells 
treated with TGF-β over a 4-day period. Scale bar represents 400 µm. (F) Protein expression of E-cadherin and N-cadherin, as measured by 
Western blot, of NMuMG cells over the treatment period. Equal loading was confirmed by α-tubulin. (G) mRNA expression of mesenchymal 
genes of untreated control NMuMG cells and 96 hr treated cells. qPCR was performed in triplicate per biological repeat (n = 4). Data shown 
as mean ± SEM. (H) mRNA expression of EMT transcription levels as assessed by qPCR performed in triplicate per biological repeat 
(n = 4). Data shown as mean ± SEM. (I) Protein expression levels of Siah1 and Siah2, as assessed by Western blot, in NMuMG cells during 
TGF-β treatment regimen. Equal loading confirmed by α-tubulin.
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Siah proteins target Zeb1 for proteasomal 
degradation
Siah proteins are ubiquitin ligases that regulate 
signal transduction by targeting substrates for proteasomal 
degradation [16]. To examine whether Siah proteins 
could alter Zeb1 protein levels, Zeb1 was overexpressed 
alongside increasing concentrations of Siah1 or Siah2 in 
the human osteosarcoma cell line, U2OS. Expression of 
either Siah1 or Siah2 was associated with decreased Zeb1 
protein abundance (Figure 3A, Supplementary Figure 3A). 
We have previously identified a peptide inhibitor of Siah 
called Phyllopod (PHYL), which blocks Siah-mediated 
degradation by preventing substrate interaction with 
Siah [24, 33]. PHYL, but not the mutant form of PHYL 
(PHYL NxN) that is unable to bind to Siah, inhibited Siah-
mediated degradation of Zeb1 (Figure 3B, Supplementary 
Figure 3B). In addition, the proteasome inhibitor MG132 
was capable of preventing the Siah-mediated reduction of 
Zeb1, demonstrating the importance of the proteasome 
in this process (Figure 3C). The half-life of Zeb1 is three 
hours, as assessed by cycloheximide (CHX) treatment 
(Figure 3D). In the presence of Siah1 or Siah2, the half-life 
of Zeb1 was reduced to two hours (Figure 3D). However, 
when co-transfected with the E3-ligase deficient RING 
mutant (RM) form of Siah1, the half-life of Zeb1 returns 
to 3 hours (Supplementary Figure 3C). The RM form of 
Siah2, however, prolongs the half-life of Zeb1 to beyond 
4 hours. These mutant forms of Siah are able to bind to 
substrates, but due to mutations in their RING regions, 
are unable to transfer ubiquitin to substrates. To examine 
the induction of Zeb1 ubiquitylation by Siah proteins, 
Siah1-RM or Siah2-RM were co-expressed with ubiquitin 
and Zeb1 in U2OS cells, in the absence or presence of 
MG132 (Figure 3E). These results demonstrate that in 
the presence of Siah1 or Siah2, there is increased Zeb1 
ubiquitylation. We next sought to determine whether Siah1 
and Siah2 interact with Zeb1 by co-immunoprecipitation 
with the RING mutant forms of Siah1 and Siah2. Using 
this approach, Zeb1 was found to co-precipitate with 
Figure 2: Siah knockdown induces an EMT gene profile. (A) The efficiency of Siah knockdown with Dharmacon SMARTpool 
siRNAs as confirmed by qPCR. (B) mRNA expression of mesenchymal genes, following Siah1 and/or Siah2 knockdown, as assessed 
by qPCR. (C) The mRNA expression of EMT transcription factors, following Siah1 and/or Siah2 knockdown, as determined by qPCR. 
(D) Knockdown of Siah1, Siah2 and Zeb1 in MCF-7 cells knockdown with Dharmacon SMARTpool siRNAs. (E) mRNA expression 
of mesenchymal genes following knockdown of Zeb1 alone, Siah1 and Siah2 or Siah1, Siah2 and Zeb1. (F) The mRNA expression of 
EMT transcription factors following Zeb1, Siah1 and Siah2, and Siah1, Siah2 and Zeb1 knockdown. All knockdown qPCR reactions 
were performed in triplicate per biological repeat (n = 5). Gene expression levels are relative to control (set value of 1). Data shown as 
mean ± SEM.
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Siah1 and Siah2, showing that Siah proteins and Zeb1 are 
binding partners (Figure 3F). Together, these results show 
that both Siah1 and Siah2 interact with and target Zeb1 for 
proteasomal degradation.
Siah2 knockout causes a mesenchymal 
phenotype in mammary carcinoma cell lines
To ascertain the functional consequences of genetic 
loss of Siah in breast cancer, we utilized the Polyoma 
Middle T (PyMT)-driven mouse model of breast cancer in 
a Siah2-/- background, as previously described [34]. Three 
independent wildtype (PyMT-WT) and five independent 
Siah2-/- (PyMT-Siah2-/-) breast cancer cell lines were 
isolated from tumors that originated from different mice 
[34]. Cells were sorted for EpCAM positivity preceding 
isolation to exclude fibroblast contamination. Assessing 
the morphology of PyMT-Siah2-/- cell lines in culture, 
we observed a mesenchymal phenotype (Figure 4A, 
Supplementary Figure 4A). In contrast, PyMT-WT 
cell lines possessed a typical epithelial morphology 
(Figure 4A, Supplementary Figure 4A). Similarly, in 
three-dimensional cell culture, PyMT-WT cells formed 
spheres without apparent invasion into surrounding matrix 
(Figure 4B, Supplementary Figure 4B). Two of the five 
PyMT-Siah2-/- cell lines, however, exhibited an invasive 
Figure 3: Siah causes reduction of Zeb1 protein levels. (A) Western blot of Zeb1 protein abundance in U2OS cells expressing Zeb1 
alongside increasing concentrations of Siah1 or Siah2 (50 ng, 250 ng, 500 ng) as indicated. Equal loading was confirmed by α-tubulin. 
(B) Siah1, Siah2, Zeb1, PHYL and PHYL NxN were expressed in U2OS cells, as indicated. Following transfection, Western blot was performed 
to determine protein expression of Zeb1 and PHYL (via HA-tag expression). Equal loading was confirmed by α-tubulin. (C) Siah1, Siah2 
and Zeb1 were expressed in cells and then treated with MG132, at concentrations and for time periods as indicated. Zeb1 protein expression 
was then assessed by Western blot. Loading was determined by α-tubulin. (D) Siah1, Siah2 and Zeb1 were expressed in U2OS cells and 
then treated with 100 µg/ml cycloheximide (CHX) for time periods as indicated. Zeb1 protein expression was then assessed by Western blot. 
Loading was determined by α-tubulin. Relative pixel intensities of Zeb1 are represented by the mean values of 3 independent experiments. 
The adjacent graph shows mean relative pixel densities ± SEM of 3 independent experiments. (E) Siah1, Siah2, Zeb1 and ubiquitin was 
expressed in U2OS cells as indicated. Cells were then incubated with MG132 and to measure protein ubiquitylation, immunoprecipitation 
of Zeb1 was performed. Ubiquitin and Zeb1 expression was analyzed by Western blot. Loading was determined by α-tubulin. 
(F) Co-immunopreciptation of Zeb1 with Siah1 RING mutant (left) and Siah2 RING mutant (right). 10% of cell lysates were used for 
analysis of input.
Oncotarget867www.impactjournals.com/oncotarget
Figure 4: PyMT-Siah2-/- cell lines undergo spontaneous EMT. (A) Phase contrast images of PyMT-WT and PyMT-Siah2-/- cells 
in 2D culture. Two representative images shown. Scale bar represents 400 µm. (B) Morphology of PyMT-WT and PyMT-Siah2-/- cells in 
3D Matrigel-embedded culture (two representative images shown, scale bar represents 100 µm). (C) Protein expression of E-cadherin 
cadherin in PyMT-WT and PyMT-Siah2-/- cell lines, as determined by Western blot (left panel), and intracellular localization as shown 
by immunofluroescence (right panel; two representative images shown, scale bar represents 100 µm). (D) Vimentin protein expression 
of PyMT-WT and PyMT-Siah2-/- cells as determined by Western blot. Equal loading was confirmed by β-actin. (E) mRNA expression of 
mesenchymal genes and E-cadherin in PyMT-WT and PyMT-Siah2-/- cells as determined by qPCR. All qPCR reactions were performed 
in triplicate per technical repeat (three technical repeats). Data shown as mean ± SEM. (F) The mRNA expression of EMT transcription 
factors in PyMT-WT and PyMT-Siah2-/- cells as determined by qPCR. All qPCR reactions were performed in triplicate per technical repeat 
(three technical repeats). Data shown as mean ± SEM. (G) Zeb1 protein levels of PyMT-WT and PyMT-Siah2-/- cells were assessed by 
Western blot. Equal loading was confirmed by α-tubulin.
phenotype, as evidenced by the branching acini, in 
three-dimensional matrices (Figure 4B, Supplementary 
Figure 4B). These data show that PyMT-Siah2-/- cell 
lines have a more mesenchymal phenotype.
Importantly, there was a decrease in E-cadherin 
gene expression in the PyMT- Siah2-/- cell lines 
(Figure 4C). At the protein level, all three PyMT-WT 
cell lines were positive for E-cadherin protein expression, 
while PyMT-Siah2-/- cell lines either had a decreased, 
or lacked, expression of E-cadherin (Figure 4C, 
Supplementary Figure 4C). Interestingly, all cell lines 
were positive, albeit to different degrees, for N-cadherin 
protein expression (Supplementary Figure 4D). Also, 
there was overall a stronger expression of Vimentin, 
an EMT marker, in PyMT-Siah2-/- cell lines compared 
to their wildtype counterparts (Figure 4D). In order to 
gauge whether the morphological differences observed 
in PyMT-Siah2-/- cell lines were associated with a change 
in mesenchymal gene expression, the mRNA abundance 
of BIN1, BGN, FBLN1 and MMP2 was measured. 
Firstly, Siah expression was evaluated in these cell lines. 
While there were varying levels of Siah1a and Siah1b 
gene expression in all cell lines, the PyMT-Siah2-/- 
cells lines, as expected, lacked Siah2 gene expression 
(Supplementary Figure 4E). Accordingly, PyMT-
Siah2-/- cell lines showed increased expression of these 
mesenchymal genes compared to PyMT-WT cell lines 
(Figure 4E, Supplementary Figure 4F). Overall, there 
was a decrease in E-cadherin gene expression (Figure 4E, 
Supplementary Figure 4F). Similarly, the expression of 
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EMT transcription factors was increased in PyMT-Siah2-/- 
cell lines (Figure 4F, Supplementary Figure 4G).
Having shown that Zeb1 is a substrate of Siah 
ubiquitin ligase function (Figure 3), we therefore expected 
increased protein expression of Zeb1 in the PyMT-Siah2-/- 
cell lines. Zeb1 protein was detected in four of the five 
PyMT-Siah2-/- cell lines, whereas all three PyMT-WT cell 
lines were negative for Zeb1 (Figure 4G). Together, these 
data demonstrate that the genetic loss of Siah2 causes 
sustained EMT in vitro, resulting in a mesenchymal 
phenotype that is associated with an increase of Zeb1 
protein abundance.
DISCUSSION
Currently, the post-translational regulatory 
mechanisms of Zeb1 are not well understood. Here we show 
that Siah proteins, a family of E3 ubiquitin ligases, are novel 
regulators of Zeb1 and therefore, EMT. Taken together, 
these data indicate that in epithelial cells, the presence of 
Siah maintains Zeb1 protein at low levels, thus preventing 
the induction of EMT (Figure 5A). However, with active 
TGF-β signaling, Siah is down-regulated, which then allows 
Zeb1 protein levels to increase, thereby inducing EMT 
(Figure 5B). Similarly, with the loss of Siah, Zeb1 protein 
levels accumulate and induce EMT (Figure 5C).
These data demonstrate that while the PyMT-
Siah2-/- cell lines were generally more mesenchymal than 
the PyMT-WT cell lines, there was strong heterogeneity 
amongst the different lines. In fact, the cell line we had 
previously used, PyMT-Siah2-/- 2, was the most epithelial 
of the PyMT-Siah2-/- cell lines and readily grew tumours 
in mice [34]. Furthermore, as Siah1 can also regulate 
Zeb1 and is itself regulated during EMT, varying levels 
of compensatory up-regulation of Siah1a and/or Siah1b 
at the protein level may be able to partially rescue the 
PyMT-Siah2-/- cell lines from a mesenchymal phenotype. 
However, it is possible that other factors may be regulating 
Siah during the EMT program. Additionally, as part of 
the purification process, cells only expressing EpCAM, 
an epithelial cells marker, were selected following 
cell isolation. This suggests that loss of Siah is able to 
naturally induce an epithelial-to-mesenchymal drift in a 
population that was initially purely epithelial. It is clear 
that the PyMT-WT cell lines are epithelial, and while there 
is variability amongst the PyMT-Siah2-/- cell lines, there is 
clearly a strong trend towards a mesenchymal phenotype.
TGF-β is known to be the primary upstream inducer 
of EMT, yet how multiple signaling pathways interact with 
Figure 5: Proposed mechanism of Siah-mediated regulation of EMT. (A) In epithelial cells, Siah expression maintains Zeb1 
protein at low levels, thereby preventing EMT induction. (B) With active TGF-β signaling, Siah expression is down-regulated, leading to 
an increase of Zeb1 protein abundance and the induction of the EMT program (C) With the loss of Siah, Zeb1 levels are unchecked and 
are then able to induce EMT.
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one another to activate EMT remains unclear. Previous 
work has identified two possible methods of hypoxia-
mediated Siah activation: phosphorylation by p38 MAPK 
and gene transcription induction through Akt signaling 
[19]. Interestingly, both of these well-known pathways 
have been shown to be targets of TGF-β [35, 36]. It is 
possible that Siah expression is modulated by TGF-β via 
both or either of these pathways. In addition to this, Siah 
is known to interact with the Ras pathway and β-catenin, 
both of which are also downstream targets of TGF-β 
signaling and associated with EMT [37–39]. Further work 
should focus on delineating the precise pathways through 
which TGF-β is acting upon Siah.
It is becoming increasingly clear that Siah may have 
a dual role, as both a tumor suppressor and an oncogene 
in cancer [17, 40]. Our work suggests that Siah may 
be acting as a tumor suppressor in the context of EMT 
and metastasis via suppression of Zeb1. By targeting 
Zeb1 for degradation, Siah may be able to prevent the 
induction or interrupt the persistence of EMT. By doing 
so, Siah may prevent tumor cells from disseminating 
from the primary tumor, thus inhibiting metastasis. EMT 
is also known to be a vital process during embryonic 
development. Interestingly, Siah1a/Siah2 double knockout 
mice are embryonic lethal and Siah2 has been shown 
to be expressed at particular sites during development 
[41, 42]. This demonstrates a level of functional 
redundancy between Siah2 and Siah1a in vivo, but is a 
possible indicator of the importance of Siah in controlling 
EMT, particularly during early development. The loss 
of both Siah1a and Siah2 may interrupt the activation of 
EMT during the developmental process, causing the death 
of these mice at the embryonic stage.
Considering the importance of Zeb1 in EMT 
initiation, the findings presented here have implications on 
our current understanding of the TGF-β signaling network, 
the regulation of Zeb1 and the molecular steps behind the 
aberrant induction of the EMT program in cancer. This 
work highlights the complexity and dynamism of EMT 
regulation and the need for a greater comprehension of 
how EMT is induced and its importance in the cancer 
setting. Understanding the mechanisms of tumor cell 
escape, survival and their subsequent colonization and 
outgrowth in secondary organs will aid in the development 
of novel treatments for metastatic cancer.
MATERIALS & METHODS
Primary cell isolation, cell culture 
and various assays
PyMT-derived tumor cell lines were generated 
as previously described [34]. Cell culture with MCF-7, 
U2OS, PyMT-WT and PyMT-Siah2-/- cells lines was 
performed as previously published [24, 34]. NMuMG cells 
were maintained in Dulbecco’s modified Eagle’s medium, 
containing 10% (v/v) fetal calf serum, 1% (w/v) penicillin/
streptomycin and 0.2% (v/v) insulin. EMT was induced 
in MCF-7 cells by a 5-day daily treatment of TGF-β 
(R&D Systems) and TNF-α (R&D Systems) at 2 ng/ml 
and 10 ng/ml, respectively. NMuMG cells were treated 
with 5 ng/ml of TGF-β (R&D Systems) daily, over several 
different time-points (1–4 days). Cells were then harvested 
for gene and protein expression analysis.
For transient siRNA-mediated knockdown, 
MCF-7 cells were seeded at a density of 1.3 × 105 cells/well, 
while NMuMG cells were seeded at a density of 
7000 cells/well, in 12-well plates the day prior to trans-
fection. DharmaFECT1 (ThermoScientific) and siRNAs 
(Dharmacon SMARTpool and individual siRNAs from 
the SMARTpool; ThermoScientific) were pre-incubated 
for 15 minutes at room temperature in serum-free media. 
Then, cells were incubated in a final transfection solution, 
comprising of 0.4% (v/v) DharmaFECT 1 and 50 nM siRNA 
in antibiotic-free media. After 24 hours, media was replaced 
and following a further 48 hours, cells were harvested for 
gene expression analysis. For transient overexpression 
assays, cells were transfected with expression plasmids 
using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions and as previously described 
[24]. Expression plasmids for Siah1, Siah2, Phyllopod VxP, 
Phyllopod NxN and Zeb1 have been described 
[24, 43]. To inhibit proteasomal activity, transfected cells 
were treated with MG132 (Merck Millipore) as indicated. 
To inhibit protein synthesis, transfected cells were treated 
with cycloheximide (Sigma-Aldrich) as indicated.
To visualize the growth of cells on plastic 
(2-dimensional growth), phase contrast images of 
cells were taken with the Evos microscope (Advanced 
Microscopy Group). To observe cell growth in 
3-dimensional suspension, cells were seeded in a mix of 
media and 2% Matrigel (BD Laboratories), in duplicate, 
on a 40 μl Matrigel bed. These cells were seeded at 
3000 cells per chamber in a 8-well chamber slide (Thermo 
Fischer Scientific). Images of cells in culture were taken 
four days later with an inverted microscope (Leica).
Co-immunoprecipitation
U2OS cells were transfected as above. 
Following recovery, cells were lysed in NP40 buffer 
containing 10 ug/ml Aprotinin and 10 ug/ml Pepstatin. 
Co-immunoprecipitation was performed as previously 
published [18]. Protein ubiquitylation was measured by 
culturing transfected cells with 5 μM MG132 for 10 hours 
and then lysing in NP40 buffer as above.
Western blotting
Cells were lysed and analyzed by Western blotting 
as described previously [24]. Primary antibodies used 
are as follows: Flag, α-tubulin, β-actin (Sigma-Aldrich); 
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E-cadherin, N-cadherin (BD Laboratories); Siah1 (as 
previously described [44]); Siah2 (Novus Biologicals); 
Siah2, Zeb1 (Santa Cruz Biotechnology); Vimentin, 
Zeb1 (Cell Signaling Technology); HA (a kind gift from 
Rick Pearson, Peter MacCallum Cancer Centre). To 
quantify Western blots, densities of bands were measured 
in Image J [45]. These values were then normalized to 
the densities of their corresponding loading control. In 
cycloheximide treatment experiments, values of samples 
were then normalized to the positive control.
mRNA and qRT-PCR
mRNA was extracted using the QiaShredder 
kit (Qiagen) and the RNeasy Plus Mini Kit (Qiagen) 
according to the manufacturer’s instructions. qRT-PCR 
was performed with converted cDNA as previously 
published [34]. Results were normalized to housekeeping 
genes CETN2 (human), and EF-1 or HMBS (mouse). 
Sequences (5′ to 3′) of primers (GeneWorks) used are as 
follows:
Mouse EF-1 Sense: CATCAACATCGTCGTAATCGGAAntisense: CTTGTCGA TTCCGCCACA T
Mouse HMBS Sense: GTGTTGCACGATCCTGAAACTAntisense: GTTGCCCATCCTTTATCACTGTA
Mouse E-cadherin Sense: CAGGTCTCCTCA TGGCTTTGCAntisense: CTTCCGAAAAGAAGGCTGTCC
Mouse N-cadherin Sense: AGCGCAGTCTTACCGAAGGAntisense: TCGCTGCTTTCATACTGAACTTT
Mouse Siah1a Sense: AAGTGTCCACCA TCCCAGAGAntisense: ATGTAAGTTTGGGGCGACAG
Mouse Siah1b Sense: GCTACAGCATTATCCACTGGCAntisense: AGGACACTCAAAAAGACTCGC
Mouse Siah2 Sense: CCAATGCCGCCAGAAGTTAAGAntisense: CAGGGAAACAGAACTGCCGA
Mouse BIN1 Sense: AGGATCTTCGGACCTATCTGGCAntisense: GGCTTCGTGCATCGCTTTAAC
Mouse TBX3 Sense: TGGAACCCGAAGAAGACGTAGAntisense: TACCCCGCTTGTGAAACTGG
Mouse FBLN1 Sense: ATCAGATGGCTAACCAGCACAAntisense: A TCCTGCACTCCTTGGA TTCT
Mouse MMP2 Sense: TTCTGGTCAAGGTCACCTGTCAntisense: CAAGTTCCCCGGCGA TGTC
Mouse Zeb1 Sense: GCTGGCAAGACAACGTGAAAGAntisense: GCCTCAGGATAAATGACGGC
Mouse Zeb2 Sense: AGGCTCGGAGACAGA TGAAGAAntisense: GCGGACAGACAGACACTTACC
Mouse Twist Sense: GGACAAGCTGAGCAAGA TTCAAntisense: CGGAGAAGGCGTAGCTGAG
Mouse Slug Sense: TGGTCAAGAAACA TTTCAACGCCAntisense: GGTGAGGATCTCTGGTTTTGGTA
Mouse Snail Sense: CACACGCTGCCTTGTGTCTAntisense: GGTCAGCAAAAGCACGGTT
Human CETN2 Sense: CGGACTCCTTTGGCTATGGCCTCAntisense: TGGTGCCAGTTCCATCCGCA




PyMT-WT and PyMT-Siah2-/- cells were seeded 
on glass coverslips in a 12-well plate at subconfluent 
levels and incubated for 24 hours to adhere. Plates were 
then fixed with methanol and stained with E-cadherin or 
N-cadherin antibodies (BD Laboratories) according to 
manufacturer’s instructions. Slides were observed with the 
Olympus BX-51 or BX-61 microscope (Olympus).
Statistical analysis
For gene expression comparison in MCF-7 and 
NMuMG untreated control and treated cells, results were 
normalized to untreated control cells. The Wilcoxon rank 
test was utilized in R to determine statistical significance. 
Data is displayed on a log10 scale. To determine 
significance in non-normalized results, the unpaired, 
two-tailed Student’s t-test was employed. For the analysis 
of siRNA-mediated knockdowns, the one sample t-test, 
with the theoretical mean set as 1, was employed when 
comparing knockdown groups to control. Data is 
displayed on a linear (Siah1 KD, Siah2 KD, Zeb1 KD) 
or a log2 scale. When comparing gene expression levels 
between PyMT-WT and PyMT-Siah2-/- cell lines, the 
Mann-Whitney test was used. Data is displayed on a log10 
scale. Statistical significance was denoted as follows: 
*p < 0.05, **p < 0.01, ***p < 0.001. Data shown is mean 
± SEM unless indicated otherwise.
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Human BIN1 Sense: CGATCTTGTTTGCCTCATCCCAntisense: TGAGCAGTGCGTCCAGAATTT
Human FBLN1 Sense: AGAGCTGCGAGTACAGCCTAntisense: AAGACCTGTCCACACTGGTAG
Human MMP2 Sense: TACAGGATCATTGGCTACACACCAntisense: GGTCACATCGCTCCAGACT
Human N-cadherin Sense: ATCGCATTATGCAAGACTGGATTAntisense: ATGCACATCCTTCGATAAGACTG
Human Slug Sense: AAGCATTTCAACGCCTCCAAAAntisense: GGATCTCTGGTTGTGGTATGACA
Human Snail Sense: TCGGAAGCCTAACTACAGCGAAntisense: AGATGAGCATTGGCAGCGAG
Human Twist Sense: GTCCGCAGTCTTACGAGGAGAntisense: GCTTGAGGGTCTGAATCTTGCT
Human Zeb1 Sense: GATGATGAATGCGAGTCAGATGCAntisense: ACAGCAGTGTCTTGTTGTTGT
Human Zeb2 Sense: CAAGAGGCGCAAACAAGCCAntisense: GGTTGGCAATACCGTCATCC
Human Siah1 Sense: TAAATGGTCATAGGCGACGAAntisense: GCAATGCTGGTGTCAAAGAC
Human Siah2 Sense: AATCACCCGGAGTGCTTATCAntisense: GGACCCTTTCCCACAATTTA
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